A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

This study is testing a new drug called LY4256984 as a potential treatment for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease) — a progressive neurological condition that causes muscle weakness and paralysis. This early-phase study is primarily evaluating safety and how the drug behaves in the body. **You may be eligible if...** - You have a definite, possible, or probable diagnosis of sporadic ALS (not inherited) - Your ALS symptoms started within the last 24 months - Your BMI is between 18.0 and 35.0 kg/m² **You may NOT be eligible if...** - You have significant heart, kidney, liver, gastrointestinal, breathing, blood, or other medical conditions - You have another neurodegenerative disease or significant memory or thinking problems - Your liver enzymes (ALT, AST) or bilirubin are significantly elevated - You have significant kidney impairment - You have an abnormal ECG (heart tracing) that the investigator considers risky - You have significant spine problems found on X-ray Talk to your doctor to see if this trial is right for you.